#ESHMDS2022 - CALL FOR ABSTRACTS: 8th Translational Research Conference on MYELODYSPLASTIC SYNDROMES

 

8th Translational Research Conference

MYELODYSPLASTIC SYNDROMES

 

April 7-10, 2022

Mandelieu-La Napoule, France

#ESHMDS2022

   

---

CALL FOR ABSTRACTS!
DEADLINE: JANUARY 23rd, 2022

Abstracts are eligible to be selected for an oral or a poster presentation.

 

---

REGISTRATION IS OPEN!

Looking forward to meeting you face to face in Mandelieu-La Napoule, France!

 

---

About the Conference:

The 8th ESH TRANSLATIONAL RESEARCH CONFERENCE ON MYELODYSPLASTIC SYNDROMES proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field.

It is open to an international audience of biologists and clinicians, including those still in-training. This translational research conference will bring together biologists and clinicians with an interest in Myelodysplastic Syndromes (MDS) in order to explore the most recent advances in the understanding of the pathogenesis and clinical behavior of the disease.

New data will be presented on how to best apply these insights to the future of MDS therapy. Diagnostic, prognostic and therapeutic issues will be presented by the faculty and ample time will be devoted to discussion with delegates.

---

CONFERENCE MAIN TOPICS:

• Disease Biology: The Genomics and its Consequences in MDS
• Disease Biology: Immune and Microenvironment Alterations and its Implications in MDS
• The Future of MDS Research
• When is MDS Really MDS, and When is it Really Bad MDS? Diagnosis and Prognosis
• Special Groups in MDS
• Treatment of MDS
• Current Progress in the Treatment of MDS
• Clinical trials in Europe and USA MDS consortium
• Late-Breaking Top News

---

LEARNING OBJECTIVES:

Upon completion of this CME activity, participants should be able to:

• Learn how to optimally diagnose MDS, mainly by morphological analysis and cytogenetics,
but also through the use of new tools, mainly molecular analysis
• Improve ability to analyze prognostic factors, including new ones
(revised IPSS, molecular analysis)
• Review current treatment of MDS, in both the high risk and low risk settings, ranging from single follow up to allogeneic stem cell transplantation
• Acquire improved knowledge of emerging treatments, based on targeted therapies and well conducted clinical trials

---

The programme will include:

Plenary Sessions - Simultaneous Meet the Experts Sessions
Keynote Lecture - Brief Oral Communications - Poster Walks
Controversial Debates - Ample time for in-depth discussion

For more information, click here!